Geneseeq Inks Deal with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS Kit in China

Geneseeq Inks与Illumina合作开发肿瘤体外诊断NGS试剂盒并在中国实现商业化

2021-03-17 05:30:12 BioSpace

本文共1430个字,阅读需4分钟

Next-generation sequencing -based precision oncology provider Geneseeq Technology Inc. , will collaborate with Illumina, Inc.  to develop comprehensive in-vitro diagnostic NGS testing kits for cancer, using Illumina's NextSeq™ 550Dx sequencing platform. The companies will work together to promote the use and application of world leading Next-Generation-Sequencing technology to enhance standards-of-care for Chinese patients. Geneseeq's comprehensive genomic profiling panel, GeneseeqPrime®, analyzes genomic alterations in 425 cancer-related genes and assesses key biomarkers, such as tumor mutation burden (TMB) and microsatellite instability (MSI).  This pan-cancer panel screens for actionable clinical next steps to therapy by providing valuable insight into key oncogenic genes and drug resistance mechanisms. In 2020, Geneseeq's TMB Testing Kit in non-small cell lung cancer (NSCLC) became the first comprehensive NGS panel entered into the Breakthrough Medical Devices Program of Chinese National Medical Products Administration (NMPA). Geneseeq will conduct all testing studies using IVD instruments and components supplied by Illumina in order to develop and commercialize the IVD kits. The IVD kits will be made available directly to patients acquiring testing services from Geneseeq, as well as hospital testing centers. According to Dr. Xue Wu, CEO and co-founder of Geneseeq Canada, this collaboration will deliver streamlined workflow and produce accurate testing results rapidly. This will help cancer patients access critical information to optimize their treatment plans, and benefit from precision medicine. "We're pleased to extend our collaboration with Geneseeq to develop assays based on the newly approved NextSeq 550Dx in China," said Li Qing, Vice President & General Manager of Greater China at Illumina. "Together with partners such as Geneseeq, we are able continuously bring in innovative NGS testing products to patients in China, and ultimately help them by unlocking the power of genome." This is the second time that the two companies joined forces to accelerate clinical availability in precision cancer care. In 2018, the two companies collaborated on the NMPA approval of the IVD kit, Essencare®(EGFR/ALK/ROS1/BRAF/KRAS/HER2 mutation testing kit, Reversible terminator sequencing) for NSCLC. About Geneseeq Geneseeq is a research-driven company providing NGS technology to accelerate precision cancer care, with headquarters located in Canada and China. It offers pan-cancer panels analyzing 400+ genes and cancer-type specific gene panels to help match patients to optimal treatments. Its CAP/CLIA/ISO15189-accredited Chinese site is equipped with advanced NGS sequencing platforms and has sequenced 420,000+ clinical samples. For more information, please visit their website and follow Geneseeq on Linkedin and Twitter. About Illumina Illumina is improving human health by unlocking the power of the genome. Its focus on innovation has established it as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Its products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with Illumina on Twitter, Facebook, LinkedIn, Instagram, and YouTube. View original content:http://www.prnewswire.com/news-releases/geneseeq-inks-deal-with-illumina-to-develop-and-commercialize-comprehensive-cancer-in-vitro-diagnostic-ngs-kit-in-china-301247592.html SOURCE Geneseeq Technology Inc.
下一代基于测序的精确肿瘤学提供商Geneseeq Technology Inc.将与Illumina公司合作,利用Illumina公司的NextSeq™550DX测序平台,开发用于癌症的综合性体外诊断NGS测试套件。两家公司将携手合作,推动世界领先的下一代测序技术的使用和应用,以提高中国患者的医疗水平。 GeneSeeq的全面基因组分析小组GeneSeeqPrime®,分析了425个癌症相关基因的基因组改变,并评估了关键的生物标志物,如肿瘤突变负担(TMB)和微卫星不稳定性(MSI)。这个泛癌小组通过提供对关键致癌基因和耐药机制的有价值的洞察力来筛选可操作的临床下一步治疗。2020年,GeneSeeq的非小细胞肺癌(NSCLC)TMB检测试剂盒成为首个进入中国国家医药产品管理局(NMPA)突破性医疗器械项目的综合性NGS面板。 Geneseeq将使用Illumina提供的IVD仪器和组件进行所有测试研究,以开发IVD套件并将其商业化。IVD试剂盒将直接提供给从Geneseeq获得检测服务的患者,以及医院检测中心。据Geneseeq加拿大公司首席执行官兼联合创始人薛武博士介绍,此次协作将交付精简的工作流程,快速产生准确的测试结果。这将帮助癌症患者获取关键信息以优化治疗方案,并从精准医疗中获益。 Illumina公司大中华区副总裁兼总经理李青说:“我们很高兴扩大与Geneseeq公司的合作,在中国开发基于新批准的NextSeq 550DX的分析方法。“与Geneseeq等合作伙伴一起,我们能够不断为中国的患者带来创新的NGS检测产品,并最终通过释放基因组的力量来帮助他们。” 这是两家公司第二次联手加速精准癌症护理领域的临床可用性。2018年,两家公司合作NMPA批准了用于NSCLC的IVD试剂盒Essencare®(EGFR/ALK/ROS1/BRAF/KRAS/HER2突变检测试剂盒,可逆终止子测序)。 关于Geneseeq Geneseeq是一家以研究为驱动的公司,提供NGS技术以加速精准癌症护理,总部位于加拿大和中国。它提供了分析400多个基因的泛癌症面板和癌症类型的特定基因面板,以帮助患者匹配最佳的治疗方法。其通过CAP/CLIA/ISO15189认证的中国站点配备了先进的NGS测序平台,已对42万多个临床样本进行了测序。欲了解更多信息,请访问他们的网站,并在Linkedin和Twitter上关注Geneseeq。 关于Illumina Illumina正在通过打开基因组的力量来改善人类健康。其对创新的专注使其成为DNA测序和基于阵列的技术的全球领先者,服务于研究、临床和应用市场的客户。其产品应用于生命科学、肿瘤学、生殖健康、农业和其他新兴领域。欲了解更多信息,请访问www.Illumina.com,并在Twitter、Facebook、LinkedIn、Instagram和YouTube上与Illumina联系。 查看原文内容:http://www.prnewswire.com/news-releases/geneseeq-inks-deal-with-illumina-to-develop-and-commercialize-complement-cancer-in-vitro-diagnostic-ngs-kit-in-china-301247592.html 源Geneseeq技术公司。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文